Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03130036 · ClinicalTrials.gov registry record · NA
Biodistribution of [11C]Acetoacetate/[18F]Fluorodeoxyglucose in Subjects With Risk Factors for Alzheimer's Disease
A NA study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- NA
- Development phase
- 42
- Enrollment target
NCT03130036 is a NA study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 42 participants.
The verdict
NCT03130036, a NA study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 42 participants
- Enrollment target
Study Summary
This is a single center imaging study that will recruit 60 participants who are enrolled in the Effect of a Ketogenic Diet on Alzheimer's Disease Biomarkers and Symptoms: Brain Energy for Amyloid Transformation in AD (BEAT-AD) Study protocol. This cohort of patients will receive a maximum of 3 \[11C\]Acetoacetate (AcAc)/\[18F\]Fluorodeoxyglucose (FDG) PET scans over 18 weeks as part of this supplemental trial.
Interventions
- OTHER [11C]Acetoacetate[18F]Fluorodeoxyglucose positron emission tomography scan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2015-06-09 |
| Est. Completion | 2024-06-19 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03130036
The ClinicalTrials.gov registry entry for NCT03130036 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [11C]Acetoacetate[18F]Fluorodeoxyglucose positron emission tomography scan is the first listed.
NCT03130036 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03130036 about?
NCT03130036 is a clinical study titled "Biodistribution of [11C]Acetoacetate/[18F]Fluorodeoxyglucose in Subjects With Risk Factors for Alzheimer's Disease". This is a single center imaging study that will recruit 60 participants who are enrolled in the Effect of a Ketogenic Diet on Alzheimer's Disease Biomarkers and Symptoms: Brain Energy for Amyloid Transformation in AD (BEAT-AD) Study protocol. This cohort of patients will receive a maximum of 3 \[11C...
What is the current status of trial NCT03130036?
This trial is currently completed. It is a NA study. The enrollment target is 42 participants. The study started on 2015-06-09. Estimated completion is 2024-06-19.
What interventions are being tested in trial NCT03130036?
The interventions under investigation include: [11C]Acetoacetate[18F]Fluorodeoxyglucose positron emission tomography scan (OTHER).
Who is sponsoring clinical trial NCT03130036?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.